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Introduction
Atrial fibrillation (AF) is the most common sustained arrhyth-
mia encountered in clinical practice, affecting more than 7 
million people in North America and Europe (Rosamond et al 
2008). AF prevalence is closely related to age, affecting 1% of 
the population <65 years of age and 5% of those > 65 years of 
age (Kannel et al 1998). AF is expected to acquire an epidemic 
aspect together with aging (Go et al 2001).
At the same time, AF contributes significantly to overall mor-
bidity and mortality rates, being associated with a significantly 
decreased quality of life, involving substantial costs, being a 
significant financial burden for sanitary systems (Conway et al 
2004; Van Wagoner 2008).
In addition, AF is difficult to treat, current strategies including 
transcatheter ablation and antiarrhythmic medication are far 
from being optimal. In this context, there are research trends 
on the substrate for AF, on the pathophysiological mechanisms 
and drug use that could stop the processes of structural and elec-
trophysiological atrial remodeling, thus decreasing the load of 
AF (Anis et al 2009).
Experimental and clinical studies have shown a causal relation-
ship between inflammation and AF. The most frequently stud-
ied vascular markers were high-sensitivity C-reactive protein 
(hs-CRP) and interleukin 6 (IL-6). The results showed signifi-
cantly higher levels of inflammatory markers in patients with 
AF than in controls with sinus rhythm.
There have been experimental studies and meta-analyses prov-
ing the involvement of the renin-angiotensin-aldosterone system 
(RAAS) in initiating and maintaining inflammatory processes 
and examining the relationship between RAAS inhibition and 
AF (Healey et al 2005). These studies have emphasized the 
beneficial effects of angiotensin-converting-enzyme inhibitors 
(ACEIs) and angiotensin receptor blockers (ARBs) in prevent-
ing AF. However, none of the trials mentioned has analyzed in 
parallel the levels of inflammatory markers (Boos et al 2006).
Therefore, the current study aimed to analyze the evolution of 
inflammatory markers in patients with paroxysmal AF prior to 
treatment with ACEIs/ARBs and 6 months after treatment, try-
ing to establish a correlation between the levels of inflammatory 
markers and the treatment with RAAS inhibitors.
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Materials and methods
Forty-five patients with paroxysmal AF from “Niculae Stancioiu” 
Heart Institute Cluj-Napoca were included in the study between 
September 2011 and February 2012. Exclusion criteria were: 
acute coronary syndrome or known ischemic heart disease (old 
myocardial infarction or aortocoronary bypass), end-stage dilated 
cardiomyopathy, valvular heart disease, myocarditis, pericardi-
tis, concomitant inflammatory diseases, cancer or diseases of the 
immune system. Patients with previous ACE inhibitor or ARB 
treatment were also excluded. All patients underwent clinical 
examination, 12-lead ECG, echocardiography determining left 
atrial volume and area, telesystolic and telediastolic volumes 
and left ventricular ejection fraction (General Electric Vivid S6 
ultrasound machine). 
The study protocol was approved by the Ethics Committee of 
“Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-
Napoca. Patients were included in the study after signing the 
informed consent.
Baseline blood samples from the forearm vein were also har-
vested from all patients using Greiner Vacuette serum clot ac-
tivator tubes and inflammatory markers were dosed -hs-CRP 
(via immunoturbidimetric method with Cobas Integra 400 ana-
lyzer) and IL-6 (via immunoenzymatic technique with immu-
no-chemiluminiscence detection method on Beckman Coulter 
Access analyzer). The lower limits of detection were 0.15 mg/L 
for hs-CRP and 0.5 pg/ml for IL-6.
All patients started treatment with perindopril (17 patients) or 
irbesartan (28 patients) in tolerated doses that would not result in 
a significant decrease in blood pressure. The same products and 
the same dosage were maintained in patients on statin therapy 
(16 patients) and in those without statin therapy, statins had not 
been deliberately introduced in order not to affect the response 
to inflammatory markers and to alter the final results, being 
aware of the antiinflammatory pleiotropic effects of these drugs.
After 6 months of treatment, the following procedures were 
resumed: clinical examination, ECG, and a new blood sample 
was collected dosing the same inflammatory markers (hs-CRP 
and IL-6) and using the same methods.
Statistical analysis was performed using MedCalc software 
version 12.7. Data were labeled as categorical and continuous 
variables. Categorical variables were analyzed using frequen-
cies and the mean and standard deviation were calculated for 
continuous variables with normal distribution. Kolmogorov 
Smirnov test was used for normality tests.
Univariate analysis of continuous variables was carried out us-
ing the t test for independent variables and Pearson’s correla-
tion and t test for conjugate variables. Univariate analysis of 
categorical variables was carried out using the Chi-Square (χ2) 
test. Analysis of variance (ANOVA) for repeated measures was 
used to determine the influence of a factor on the variation of a 
variable after 6 months of treatment with sartans/ACEIs. The 
p value <0.05 was found statistically significant.
Results
Only 38 of the 45 patients included in the study reached the end. 
Three patients were excluded because they did not tolerate study 
medication even in low doses, resulting in significantly lower 
blood pressure. Two other patients did not take their medication 
regularly and two patients did not join the study for personal 
reasons. Therefore, the final analysis consisted of 38 patients (13 
patients on perindopril and 25 on irbesartan), all with hs-CRP 
and IL-6 levels lower than 10 mg/L and 10 pg/ml respectively.
Patients had a mean age of 56.5±9.4 years (35-72 years), 22 
(57.9%) were male and 16 (42.1%) female.
Clinical and laboratory characteristics of patients can be seen 
in Table 1.
Table 1. Clinical and laboratory characteristics of patients
During the six month follow-up, 5 patients (13.15%) had elec-
trocardiographically documented recurrent episodes of  AF and 
other 15 (39.47%) had short episodes of clinical tachyarrhyth-
mias not documented electrocardiographically, which can be 
interpreted with great probability as self-limited episodes of AF.
Hs-CRP levels measured before treatment were of higher statisti-
cal significance than those measured during follow up (p=0.01).
IL-6 levels measured before treatment were of higher statistical 
significance than those measured after treatment (p=0.002; fig.1).
To determine whether there are parameters that influence the 
variation in hs-CRP levels after 6 months of treatment with 
sartans/ACE inhibitors, we first examined the possible associa-
tion between different variables and baseline levels of hs-CRP. 
After applying Pearson’s correlation, we have shown that hs-
CRP levels were not correlated with age (r=-0.110; p=0.5), AF 
Variable
Sartan 
group (n=25)
ACEI group 
(n=13)
p
AF age (mean±SD) 7.9±7.1 3.9±1.8 0.06
Number of episodes 
(mean±SD) 10.5±7.6 4.5±3.9 0.01
High blood pressure 
(N; %) 19 (76%) 9 (69.2%) 0.9
BMI (mean±SD) 27.7±4.1 25.9±3.9 0.2
Obesity (N; %) 18 (72%) 5 (38.4%) 0.09
Systolic blood pressure 
(mean±SD) 132.6±15 131.1±17.9 0.7
Diastolic blood 
pressure (mean±SD) 81.8±9.2 83.5±11.2 0.5
Left atrial diameter 
(mean±SD) 37.2±4.7 38.3±5.6 0.5
Left atrial surface 
area (mean±SD) 21.2±2.3 22.5±5 0.2
Left atrial volume 
(mean±SD) 48.2±12.6 53.4±15.4 0.2
LVEF (mean±SD) 61.9±7.4 62±8.1 0.9
Baseline hs-CRP 
(mean±SD) 3.3±2.7 2.8±2.5 0.6
Resumed hs-CRP 
(mean±SD) 3±2.2 2.5±1.8 0.5
Baseline IL-6 
(mean±SD) 3.7±2.5 2.4±2.3 0.1
Resumed IL-6 
(mean±SD) 2.7±2.2 2.2±1.5 0.5Roşianu et al 2013
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age (r=-0.259; p=0.1), body surface (r=-0.133; p=0.4), BMI 
(r=0.266; p=0.4), left atrial volume (r=0.258; p=0.1), left atrial 
volume indexed to body surface (r=0.313; p=0.6), LV end-dias-
tolic volume (r=0.044; p=0.7), LV end-systolic volume (r=0.158; 
p=0.3) and LVEF (r=0.213, p=0.1). We found a correlation be-
tween hs-CRP levels and the number of episodes of AF (r=0.359; 
p=0.02; fig. 3), left atrial diameter (r=0.410; p=0.01; fig. 4), left 
atrial surface area (r=0.323, p=0.04), left atrial volume indexed 
to body surface area (r=0.402, p=0.01), interventricular septum 
(IVS; r=0.597; p<0.001) and left ventricle posterior wall thick-
ness (LVPW; r=0.461; p=0.004).
Fig. 1. Hs-PCR levels measured before and after treatment
Fig. 2. IL-6 levels measured before and after treatment
Fig. 3. Correlation between the number of AF episodes and the 
baseline hs-CRP levels
Fig. 4.Correlation between LA diameter and the baseline hs-
CRP levels
Fig. 5. Variation in CRP levels according to IVS values
Fig. 6. Variation in CRP levels according to IVS and LVPW values
Levels of Hs-CRP did not differ by sex (p=0.2), dyslipidemia 
(p=0.8) or obesity (t p=0.1). Hs-CRP levels were higher in pa-
tients with hypertension (p=0.04).Roşianu et al 2013
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LA diameter and IVS thickness have been associated with chang-
es in hs-CRP levels (p=0.03; p=0.002 respectively). Patients 
with INS and LVPW thickness higher than normal (>10mm) 
revealed a more obvious decrease in hs-CRP levels after treat-
ment with sartans/ACE inhibitors than those with normal IVS 
and LFPW values (p=0.005; p=0.009 respectively; fig. 5 and 6).
Patients with hypertension mostly benefited from treatment with 
sartans/ACE inhibitors, regarding the reduction in hs-CRP lev-
els (p=0.05; fig. 7).
Fig. 7. Variation in hs-CRP levels depending on the presence 
of hypertension
To determine if there are parameters that influence the variation 
in IL-6 levels after 6 months of treatment with sartans/ACEIs, 
we first examined the possible association between different 
variables and baseline IL-6 levels. After applying Pearson’s 
correlation we found a correlation between IL-6 levels and the 
number of AF episodes (r=0.410; p=0.01, fig. 8), area (r=0.369; 
p=0.02; fig. 9) and left atrial volume indexed to body surface 
area (r=0.322; p=0.05).
Fig. 8. Correlation between IL-6 baseline levels and the num-
ber of AF episodes
Fig. 9. Correlation between IL-6 baseline levels and left atrial 
volume indexed to body surface area
Discussion
The most important remark of this study is that in patients with 
paroxysmal AF treated with RAAS blockers, there was a statis-
tically significant decrease in inflammatory markers represented 
by hs-CRP and IL-6.
Based on Bruins’ observation in 1997, many studies have shown 
elevated levels of hs-CRP in patients with AF compared to those 
in sinus rhythm. Moreover, patients with persistent AF had higher 
hs-CRP levels than those with paroxysmal AF and both groups 
had higher levels than those in sinus rhythm (Chung et al 2001). 
Other studies analyzing IL-6 as a marker of inflammation found 
similar distribution (Scridon et al 2012). Even though the dif-
ference was not statistically significant in all studies, there was 
a general decreasing trend from permanent AF to sinus rhythm.
There are few studies that have attempted to highlight the source 
of inflammation in patients with AF. Peripheral and central-blood 
samples were collected (coronary sinus, left atrium and pulmo-
nary veins) and inflammatory markers were dosed. Surprisingly, 
no significant differences were revealed between central and 
peripheral values. On the contrary, there were slightly higher 
peripheral than central blood values suggesting that the inflam-
matory process in paroxysmal and persistent AF is low and the 
changes appear to be transient events in the evolution of AF 
(Liubla et al 2008; Scridon et al 2012). 
Experimentally, a direct pathophysiological connection was 
showed between inflammation and left atrial fibrosis in patients 
with AF within the process of structural and electrical atrial re-
modeling. Recent studies based on nuclear magnetic resonance 
with very good imaging documentation (Utah classification) 
showed that there is a direct relationship between fibrosis and 
duration of AF, with extensive fibrosis (Utah4) being mostly 
common in patients with permanent AF and significantly lower 
(Utah 1 or 2) in patients with paroxysmal AF or in sinus rhythm 
(Akoum et al 2011).  
Angiotensin II has been proved to have a number of pro-inflam-
matory properties. It increases the production of pro-inflamma-
tory cytokines (IL-6, IL-8, TNFα, IFNγ), adhesion molecules 
(VCAM and ICAM), chemoattractant proteins (MCP -1) and of 
P-selectin and L-selectin. Angiotensin II also regulates cardiac 
fibroblast proliferation by binding angiotensin II type I receptors Roşianu et al 2013
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and stimulates the formation of fibrous tissue by promoting the 
synthesis of TGF β1, which in turn seems to be of particular 
importance in promoting atrial fibrosis (Tamarat et al 2011).
Increased production of angiotensin II stimulated after myo-
cardial infarction causes cardiac fibrosis and LV remodeling. 
Similarly, rapid atrial frequencies produce increased plasma lev-
els of angiotensin converting enzyme and angiotensin II, lead-
ing to the activation of fibroblasts, fibrosis and consequently to 
electrical conduction heterogeneity in atrial tissue. Angiotensin 
II is also involved in atrial electrical remodeling by increasing 
the slow component of the delayed-rectifier potassium current 
(IKs) resulting in decreased atrial refractoriness (Willems et al 
2001; Healey et al 2005).
There is sufficient evidence showing involvement of angioten-
sin II in the pathophysiology of AF and it seems logical that the 
administration of RAAS inhibitors (ACE inhibitors and ARBs) 
would have, theoretically, a role in preventing new episodes of 
AF and reducing AF relapse. Especially in today’s context of 
drug therapy which proves to be insufficient in restoring and 
maintaining sinus rhythm, RAAS inhibitors exert a series of 
beneficial effects: hemodynamic changes, modulation of au-
tonomic tone, reduced atrial fibrosis, modulation of refractori-
ness and the function of ion channels, likely to turn these drug 
classes into attractive partners in the treatment of AF (Ehlich 
et al 2006; Nattel et al 2007).
A large number of studies and several meta-analyzes have ex-
amined the relationship between RAAS inhibition and AF (Boos 
et al 2006). The most recent meta-analysis, published in 2011, 
which included 21 studies and 9138 patients with AF treated 
with ACE inhibitors/ARBs showed a relative reduction of 25% 
in the risk of AF (Huang et al 2011).
Clinically, our study was characterized by a low recurrence 
(52.62 %) of episodes of AF within the six months of follow up. 
The percentage may be underestimated given that there was no 
long-term Holter monitoring to outline short episodes of parox-
ysmal, self-limited AF, and the follow-up was short.
Some of the mechanisms that could explain the favorable ef-
fects of ACEIs and ARBs in preventing AF are: decreased atri-
al extent, decreased left ventricular end-diastolic pressure and 
subsequent decreased left atrial pressure, prevention of atrial 
fibrosis, change in sympathetic tonus, change in ionic currents 
and atrial refractoriness and direct antiarrhythmic effect.
A drawback of these studies lies in their lack of a parallel anal-
ysis of the beneficial effect of preventing AF together with the 
dynamics of the inflammatory markers (Boos et al 2006). Many 
studies have compared the study medication with placebo in pa-
tients with similar characteristics. As shown, the inflammatory 
process in AF is low and may be influenced by multiple factors.
Therefore, in order to eliminate any potential elements that can 
make a difference between the groups of patients, our study used 
the patient group as its own control group, analyzing inflam-
matory markers before and after treatment with ACEIs / ARBs.
It has been speculated that the decrease in the AF load in these 
patients could only be accomplished by lowering blood pres-
sure. Therefore, our study included patients with normal blood 
pressure or no more than stage 1 hypertension, administrating 
clinically tolerated doses of RAAS inhibitors.
The pleiotropic anti-inflammatory effect of statins is also well 
known. Several studies have shown a significant reduction of 
CRP or hs-PCR levels in addition to the lipid-lowering effect in 
patients treated with statins (Albert et al 2001). To avoid such 
an influence, we kept the same doses of statins in patients who 
were already receiving them, and in those without statin therapy 
we have not deliberately initiated this medication.
From our knowledge, this is the first study that analyzes the evo-
lution of paroxysmal AF and the levels of inflammatory mark-
ers in parallel with the administration of RAAS inhibitors. The 
results show a clear decrease in hs-CRP and IL-6 levels when 
using the therapy with ACEIs/ARBs in patients with paroxysmal 
AF and without other associated diseases (severe hypertension, 
CI, inflammatory processes) or other synergistic treatments.
Only two study medications were used in order to achieve more 
homogeneous patient groups: perindopril (ACE inhibitor) and 
irbesartan (ARB). The parallel analysis of patients treated with 
perindopril in comparison to those treated with irbesartan re-
sulted in the discovery of similar clinical characteristics for 
both groups. There were also no statistically significant dif-
ferences between the levels of inflammatory markers, which 
demonstrated the similar protective ability of the two drugs. 
Results are similar to literature data showing that there are no 
significant differences between ACEIs and ARBs in terms of 
their ability to reduce the risk of AF recurrence (Yin et al 2006; 
Jibrini et al 2008). 
In the present study, patients with left ventricular hypertrophy 
(LVH, defined by IVS and LVPW thickness >10 mm) and hy-
pertension showed a higher decrease in hs-CRP levels than 
those without LVH and with normal blood pressure. This can 
be explained by the well-known effect of reverse remodeling 
of RAAS inhibitors, which together with lowering blood pres-
sure also achieve a decrease in myocardial mass. Normalization 
of blood pressure and lowering diastolic pressure determine 
positive repercussions on atrial load, resulting in lower atrial 
pressure and lower parietal stretching pressure in the atrium, 
causing a process of reverse atrial remodeling. This may gen-
erate reduced hs-CRP levels together with the pleiotropic anti-
inflammatory effect of RAAS inhibitors.
One of the limitations is represented by the small number of 
patients, partially explained by the fairly demanding exclusion 
criteria, including that of finding patients with paroxysmal AF 
without treatment with ACEIs / ARBs, preferably without hy-
pertension. A multicenter study could help achieve results in a 
larger group of patients in the future.
Another limitation could be the relatively short follow-up period 
of six months, but which was synchronized with the duration 
of previous studies conducted on a larger number of patients. 
It would have been interesting to extend the follow-up to one 
year or more, but this was not possible out of financial reasons, 
analysis kits being purchased from own financial resources, as 
was the funding for the entire study.
Conclusions
Treatment with RAAS inhibitors reduces the level of inflam-
matory markers in patients with paroxysmal AF.
Treatment with RAAS inhibitors causes a greater decrease in 
hs-CRP levels in hypertensive patients with LVH than in pa-
tients with normal blood pressure and without LVH.
ACEIs and ARBs, acting on the cardiac substrate and reducing 
the inflammatory process, may have a protective therapeutic 
role of decreasing the incidence of atrial fibrillation.Roşianu et al 2013
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